查看購物車
  • English
  • Japanese
  • Korean
封面
市場調查報告書
商品編碼
1964130

幽門螺旋桿菌診斷市場－全球產業規模、佔有率、趨勢、機會、預測：按類型、技術、最終用戶、地區和競爭格局分類，2021-2031年

Helicobacter Pylori Diagnostics Market - Global Industry Size, Share, Trends, Opportunity, and Forecast, Segmented By Type, By Technology, By End user, By Region & Competition, 2021-2031F
出版日期: | 出版商: TechSci Research | 英文 181 Pages | 商品交期: 2-3個工作天內

價格

We offer 8 hour analyst time for an additional research. Please contact us for the details.

簡介目錄

全球幽門螺旋桿菌診斷市場預計將從 2025 年的 6.0578 億美元成長到 2031 年的 7.8032 億美元，複合年成長率為 4.31%。

該領域涵蓋了用於檢測胃黏膜細菌定植的侵入性和非侵入性診斷工具，例如尿素呼吸檢測、糞便抗原切片檢查。市場成長的主要促進因素是全球消化性潰瘍的高發病率以及透過早期識別病原體來降低胃癌風險的緊迫性。根據美國胃腸病學會2024年報告，北美幽門螺旋桿菌感染率仍然很高，在30%至40%之間波動，凸顯了臨床上對準確診斷干預措施的持續需求。

市場概覽
預測期 2027-2031
市場規模：2025年 6.0578億美元
市場規模：2031年 780,320,000 美元
複合年成長率：2026-2031年 4.31%
成長最快的細分市場 免疫檢測
最大的市場 北美洲

市場擴張的主要障礙之一是開發中國家實施高精度檢測所面臨的經濟和物流難題。儘管這些地區承受著最沉重的感染負擔，但先進的非侵入性診斷技術高成本，且檢查室基礎設施不足，往往阻礙了廣泛的篩檢和監測活動。這種可及性差距限制了資源匱乏地區的市場滲透率，並限制了整體收入潛力，儘管患者群體龐大。

市場促進因素

幽門螺旋桿菌相關性消化性潰瘍和胃癌發生率的上升是推動市場成長的主要動力。由於這種病原體是非幽門胃癌最強的特異性危險因素，臨床指引越來越強調根除治療，而根除治療高度依賴準確的早期診斷來預防惡性進展。長期感染與腫瘤之間的這種直接關聯正在推動篩檢的增加，尤其是在優先考慮早期療育的高風險地區。 2024年2月，國際癌症研究機構（IARC）強調了這一情況的緊迫性，指出2022年全球報告了約97萬例新發胃癌病例，並重申了早期細菌檢測對於降低腫瘤風險的重要性。

同時，由於人們的偏好從侵入性切片檢查顯著轉向呼吸檢測和糞便抗原檢測，診斷格局正在轉變。醫療系統和患者擴大選擇非侵入性檢測方法，因為與內視鏡檢查相比，這些方法具有成本更低、更便捷、操作更舒適等優勢。這一趨勢在主要診斷設備製造商的財務表現中得到了清晰的體現。例如，大塚控股株式會社在2024年2月報告稱，其2023會計年度醫療設備部門的銷售額達到156.4億日元，其中大部分來自尿素呼吸檢測系統。此外，Fasom Pharmaceuticals公司估計，光是2024年美國就有1.15億人感染，這代表著診斷應用領域一個非常巨大的潛在市場。

市場挑戰

在開發中國家推廣高精度檢測有顯著的經濟和物流障礙，嚴重限制了全球幽門螺旋桿菌診斷市場的成長。儘管這些地區的細菌定植率最高，但非侵入性檢測的高成本使得大規模篩檢在經濟上難以實現。這種價格差異實際上將很大一部分潛在患者群體排除在目標市場之外，因為在醫療資源匱乏的環境中，急性治療優先於預防性監測。因此，診斷試劑生產商錯失了在潛在需求最大的地區創造收入的機會。

此外，檢查室基礎設施的匱乏嚴重限制了精準檢測方法的擴充性。許多診斷通訊協定需要專用設備，而資金不足的醫療中心往往難以獲得這些設備，迫使它們依賴經驗性治療，從而延緩了最新技術的應用。考慮到持續存在的疾病負擔，這種機會成本巨大。根據美國胃腸病學會2024年的報告，全球兒童和青少年幽門螺旋桿菌感染率仍高達35.1%。這項數據證實，由於物流障礙，現有市場策略無法觸及的感染源依然存在。

市場趨勢

在傳統經驗性治療方法失敗率不斷上升的背景下，抗菌藥物敏感性檢測（AST）技術的廣泛應用正在從根本上改變幽門螺旋桿菌的臨床治療方式。隨著全球抗生素抗藥性達到臨界水平，醫療機構在開立處方前，優先考慮能夠識別細菌抗藥性譜（尤其是對克拉黴素和甲硝唑的抗藥性）的診斷工具。這種從簡單檢測到詳細藥敏分析的轉變對於避免無效治療方法和合理管理抗生素使用至關重要。美國國立衛生研究院（NIH）2024年12月發布的報告顯示，兒童對甲硝唑和克拉黴素的初始抗藥性數據分別為35.3%和32.6%，凸顯了市場對能夠提供全面抗藥性數據的診斷工具的迫切需求。

同時，人們對「個人化精準醫療診斷」的興趣日益濃厚，這種診斷方式利用基因型資訊為每位患者制定最佳的根除策略。這一趨勢正推動市場發展超越簡單的陽性/陰性判定，並促進分子檢測的應用，從而根據患者特定的細菌菌株指導選擇最有效的一線治療方案。透過將基因型抗藥性檢測整合到常規臨床實踐中，臨床醫師可以顯著改善治療效果，優於傳統的試驗誤法。在2025年5月舉行的消化疾病週（DDW）上，有報告指出，在將基因型抗藥性檢測作為第一線治療指南後，根除成功率從77%（經驗性治療）提高到93%。這充分展現了精準診斷的臨床和商業性價值。

目錄

第1章概述

第2章：調查方法

第3章執行摘要

第4章：客戶心聲

第5章：全球幽門螺旋桿菌診斷市場展望

  • 市場規模及預測
    • 按金額
  • 市佔率及預測
    • 按類型（設備、試劑、服務）
    • 依技術分類（免疫檢測、即時檢測、分子診斷）
    • 依最終使用者（醫院/診所、門診中心、其他）分類
    • 按地區
    • 按公司（2025 年）
  • 市場地圖

第6章：北美幽門螺旋桿菌診斷市場展望

  • 市場規模及預測
  • 市佔率及預測
  • 北美洲：國別分析
    • 美國
    • 加拿大
    • 墨西哥

第7章：歐洲幽門螺旋桿菌診斷市場展望

  • 市場規模及預測
  • 市佔率及預測
  • 歐洲：國別分析
    • 德國
    • 法國
    • 英國
    • 義大利
    • 西班牙

第8章：亞太地區幽門螺旋桿菌診斷市場展望

  • 市場規模及預測
  • 市佔率及預測
  • 亞太地區：國別分析
    • 中國
    • 印度
    • 日本
    • 韓國
    • 澳洲

第9章：中東和非洲幽門螺旋桿菌診斷市場展望

  • 市場規模及預測
  • 市佔率及預測
  • 中東與非洲：國別分析
    • 沙烏地阿拉伯
    • 阿拉伯聯合大公國
    • 南非

第10章：南美幽門螺旋桿菌診斷市場展望

  • 市場規模及預測
  • 市佔率及預測
  • 南美洲：國別分析
    • 巴西
    • 哥倫比亞
    • 阿根廷

第11章 市場動態

  • 促進因素
  • 任務

第12章 市場趨勢與發展

  • 併購
  • 產品發布
  • 近期趨勢

第13章：全球幽門螺旋桿菌診斷市場：SWOT分析

第14章：波特五力分析

  • 產業競爭
  • 新進入者的潛力
  • 供應商的議價能力
  • 顧客權力
  • 替代品的威脅

第15章 競爭格局

  • Thermo Fisher Scientific inc.
  • Biohit Oyj
  • Quest Diagnostics Incorporated
  • Meridian Bioscience
  • Bio-Rad Laboratories
  • Alpha Laboratories Ltd
  • F. Hoffmann-La Roche Ltd
  • Coris BioConcept
  • Certest Biotec
  • Epitope Diagnostics, Inc

第16章 策略建議

第17章：關於研究公司及免責聲明

簡介目錄
Product Code: 21969

The Global Helicobacter Pylori Diagnostics Market is projected to expand from USD 605.78 Million in 2025 to USD 780.32 Million by 2031, registering a Compound Annual Growth Rate (CAGR) of 4.31%. This sector encompasses a range of invasive and non-invasive diagnostic tools, including urea breath tests, stool antigen assays, and endoscopic biopsies, which are essential for detecting bacterial colonization in the gastric mucosa. The primary catalyst for market growth is the high global prevalence of peptic ulcers and the urgent necessity to lower gastric cancer risks through early pathogen identification. As reported by the American College of Gastroenterology in 2024, Helicobacter pylori infection rates in North America remain significant, fluctuating between 30% and 40%, highlighting a sustained clinical requirement for accurate diagnostic interventions.

Market Overview
Forecast Period2027-2031
Market Size 2025USD 605.78 Million
Market Size 2031USD 780.32 Million
CAGR 2026-20314.31%
Fastest Growing SegmentImmunoassays
Largest MarketNorth America

One major hurdle impeding market expansion is the economic and logistical difficulty of implementing high-precision testing in developing nations. Although these regions suffer the heaviest infection burdens, the high cost of advanced non-invasive diagnostics and inadequate laboratory infrastructure often preclude widespread screening and surveillance efforts. This gap in accessibility limits market penetration in resource-poor settings, thereby constraining the overall revenue potential despite the existence of a vast patient population.

Market Driver

The escalating incidence of H. pylori-associated peptic ulcers and gastric cancer acts as the primary engine for market growth. Since this pathogen is the strongest identifiable risk factor for non-cardia gastric cancer, clinical guidelines increasingly mandate eradication therapy, which relies heavily on accurate initial diagnosis to prevent malignancy. This direct correlation between long-term infection and oncology drives screening volumes, particularly in high-risk regions where early intervention is prioritized. The International Agency for Research on Cancer highlighted this urgency in February 2024, noting that stomach cancer accounted for approximately 970,000 new cases globally in 2022, underscoring the critical need for early bacterial detection to mitigate oncological risks.

Simultaneously, the diagnostic landscape is being transformed by a marked shift in preference from invasive biopsies to breath and stool antigen tests. Healthcare systems and patients increasingly favor non-invasive modalities due to their lower cost, ease of use, and reduced procedural discomfort compared to endoscopic methods. This trend is evident in the financial performance of major diagnostic manufacturers; for instance, Otsuka Holdings Co., Ltd. reported in February 2024 that its Medical Devices division generated 15,640 million yen in sales for fiscal 2023, largely driven by urea breath test systems. Furthermore, Phathom Pharmaceuticals estimated in 2024 that there are 115 million infected individuals in the United States alone, representing a substantial addressable market for diagnostic utilization.

Market Challenge

Significant economic and logistical barriers to deploying high-precision testing in developing nations constitute a major impediment to the growth of the Global Helicobacter Pylori Diagnostics Market. While these regions exhibit the highest density of bacterial colonization, the substantial costs of non-invasive modalities render them financially inaccessible for widespread screening. This pricing disparity effectively excludes a vast segment of the potential patient pool from the addressable market, as healthcare systems in low-resource settings prioritize acute care over preventative surveillance. Consequently, diagnostic manufacturers face diminished revenue realization in geographies that hold the highest volume of latent demand.

Moreover, the deficiency in laboratory infrastructure severely limits the scalability of accurate detection methods. Many diagnostic protocols require specialized equipment that is often unavailable in underfunded medical centers, forcing reliance on empiric treatment and stalling the adoption of modern technologies. The magnitude of this missed opportunity is significant given the persistent disease burden; according to the American Gastroenterological Association in 2024, the global prevalence of Helicobacter pylori infection among children and adolescents persists at 35.1%. This statistic confirms a continuous reservoir of infection that current market strategies fail to reach due to these logistical barriers.

Market Trends

The rise of Antimicrobial Susceptibility Testing capabilities is fundamentally altering the clinical approach to Helicobacter pylori management, driven by the escalating failure rates of traditional empiric therapies. With global antibiotic resistance reaching critical levels, healthcare providers are increasingly prioritizing diagnostic tools that can identify specific bacterial resistance profiles, particularly for clarithromycin and metronidazole, prior to prescribing treatment. This transition from simple detection to detailed susceptibility profiling is essential to prevent the administration of ineffective regimens and to steward antibiotic use. According to the National Institutes of Health in December 2024, primary resistance rates among children were reported at 35.3% for metronidazole and 32.6% for clarithromycin, underscoring the urgent market demand for diagnostics that provide comprehensive resistance data.

Concurrently, a shift toward Personalized Precision Medicine Diagnostics is gaining traction, leveraging genotypic insights to tailor eradication strategies for individual patients. This trend moves the market beyond binary positive/negative results, encouraging the adoption of molecular assays that guide the selection of the most efficacious first-line therapies based on the patient's specific bacterial strain. By integrating genotypic resistance testing into routine care, clinicians can significantly improve treatment outcomes compared to standard trial-and-error methods. According to Digestive Disease Week in May 2025, the implementation of genotypic resistance testing to guide first-line therapy increased eradication success rates to 93%, compared to just 77% with empiric therapy, validating the clinical and commercial value of precision diagnostics.

Key Market Players

  • Thermo Fisher Scientific inc.
  • Biohit Oyj
  • Quest Diagnostics Incorporated
  • Meridian Bioscience
  • Bio-Rad Laboratories
  • Alpha Laboratories Ltd
  • F. Hoffmann-La Roche Ltd
  • Coris BioConcept
  • Certest Biotec
  • Epitope Diagnostics, Inc

Report Scope

In this report, the Global Helicobacter Pylori Diagnostics Market has been segmented into the following categories, in addition to the industry trends which have also been detailed below:

Helicobacter Pylori Diagnostics Market, By Type

  • Instruments
  • Reagents
  • Services

Helicobacter Pylori Diagnostics Market, By Technology

  • Immunoassays
  • POC
  • Molecular Diagnostics

Helicobacter Pylori Diagnostics Market, By End user

  • Hospitals & Clinics
  • Ambulatory Care Centers
  • Others

Helicobacter Pylori Diagnostics Market, By Region

  • North America
    • United States
    • Canada
    • Mexico
  • Europe
    • France
    • United Kingdom
    • Italy
    • Germany
    • Spain
  • Asia Pacific
    • China
    • India
    • Japan
    • Australia
    • South Korea
  • South America
    • Brazil
    • Argentina
    • Colombia
  • Middle East & Africa
    • South Africa
    • Saudi Arabia
    • UAE

Competitive Landscape

Company Profiles: Detailed analysis of the major companies present in the Global Helicobacter Pylori Diagnostics Market.

Available Customizations:

Global Helicobacter Pylori Diagnostics Market report with the given market data, TechSci Research offers customizations according to a company's specific needs. The following customization options are available for the report:

Company Information

  • Detailed analysis and profiling of additional market players (up to five).

Table of Contents

1. Product Overview

  • 1.1. Market Definition
  • 1.2. Scope of the Market
    • 1.2.1. Markets Covered
    • 1.2.2. Years Considered for Study
    • 1.2.3. Key Market Segmentations

2. Research Methodology

  • 2.1. Objective of the Study
  • 2.2. Baseline Methodology
  • 2.3. Key Industry Partners
  • 2.4. Major Association and Secondary Sources
  • 2.5. Forecasting Methodology
  • 2.6. Data Triangulation & Validation
  • 2.7. Assumptions and Limitations

3. Executive Summary

  • 3.1. Overview of the Market
  • 3.2. Overview of Key Market Segmentations
  • 3.3. Overview of Key Market Players
  • 3.4. Overview of Key Regions/Countries
  • 3.5. Overview of Market Drivers, Challenges, Trends

4. Voice of Customer

5. Global Helicobacter Pylori Diagnostics Market Outlook

  • 5.1. Market Size & Forecast
    • 5.1.1. By Value
  • 5.2. Market Share & Forecast
    • 5.2.1. By Type (Instruments, Reagents, Services)
    • 5.2.2. By Technology (Immunoassays, POC, Molecular Diagnostics)
    • 5.2.3. By End user (Hospitals & Clinics, Ambulatory Care Centers, Others)
    • 5.2.4. By Region
    • 5.2.5. By Company (2025)
  • 5.3. Market Map

6. North America Helicobacter Pylori Diagnostics Market Outlook

  • 6.1. Market Size & Forecast
    • 6.1.1. By Value
  • 6.2. Market Share & Forecast
    • 6.2.1. By Type
    • 6.2.2. By Technology
    • 6.2.3. By End user
    • 6.2.4. By Country
  • 6.3. North America: Country Analysis
    • 6.3.1. United States Helicobacter Pylori Diagnostics Market Outlook
      • 6.3.1.1. Market Size & Forecast
        • 6.3.1.1.1. By Value
      • 6.3.1.2. Market Share & Forecast
        • 6.3.1.2.1. By Type
        • 6.3.1.2.2. By Technology
        • 6.3.1.2.3. By End user
    • 6.3.2. Canada Helicobacter Pylori Diagnostics Market Outlook
      • 6.3.2.1. Market Size & Forecast
        • 6.3.2.1.1. By Value
      • 6.3.2.2. Market Share & Forecast
        • 6.3.2.2.1. By Type
        • 6.3.2.2.2. By Technology
        • 6.3.2.2.3. By End user
    • 6.3.3. Mexico Helicobacter Pylori Diagnostics Market Outlook
      • 6.3.3.1. Market Size & Forecast
        • 6.3.3.1.1. By Value
      • 6.3.3.2. Market Share & Forecast
        • 6.3.3.2.1. By Type
        • 6.3.3.2.2. By Technology
        • 6.3.3.2.3. By End user

7. Europe Helicobacter Pylori Diagnostics Market Outlook

  • 7.1. Market Size & Forecast
    • 7.1.1. By Value
  • 7.2. Market Share & Forecast
    • 7.2.1. By Type
    • 7.2.2. By Technology
    • 7.2.3. By End user
    • 7.2.4. By Country
  • 7.3. Europe: Country Analysis
    • 7.3.1. Germany Helicobacter Pylori Diagnostics Market Outlook
      • 7.3.1.1. Market Size & Forecast
        • 7.3.1.1.1. By Value
      • 7.3.1.2. Market Share & Forecast
        • 7.3.1.2.1. By Type
        • 7.3.1.2.2. By Technology
        • 7.3.1.2.3. By End user
    • 7.3.2. France Helicobacter Pylori Diagnostics Market Outlook
      • 7.3.2.1. Market Size & Forecast
        • 7.3.2.1.1. By Value
      • 7.3.2.2. Market Share & Forecast
        • 7.3.2.2.1. By Type
        • 7.3.2.2.2. By Technology
        • 7.3.2.2.3. By End user
    • 7.3.3. United Kingdom Helicobacter Pylori Diagnostics Market Outlook
      • 7.3.3.1. Market Size & Forecast
        • 7.3.3.1.1. By Value
      • 7.3.3.2. Market Share & Forecast
        • 7.3.3.2.1. By Type
        • 7.3.3.2.2. By Technology
        • 7.3.3.2.3. By End user
    • 7.3.4. Italy Helicobacter Pylori Diagnostics Market Outlook
      • 7.3.4.1. Market Size & Forecast
        • 7.3.4.1.1. By Value
      • 7.3.4.2. Market Share & Forecast
        • 7.3.4.2.1. By Type
        • 7.3.4.2.2. By Technology
        • 7.3.4.2.3. By End user
    • 7.3.5. Spain Helicobacter Pylori Diagnostics Market Outlook
      • 7.3.5.1. Market Size & Forecast
        • 7.3.5.1.1. By Value
      • 7.3.5.2. Market Share & Forecast
        • 7.3.5.2.1. By Type
        • 7.3.5.2.2. By Technology
        • 7.3.5.2.3. By End user

8. Asia Pacific Helicobacter Pylori Diagnostics Market Outlook

  • 8.1. Market Size & Forecast
    • 8.1.1. By Value
  • 8.2. Market Share & Forecast
    • 8.2.1. By Type
    • 8.2.2. By Technology
    • 8.2.3. By End user
    • 8.2.4. By Country
  • 8.3. Asia Pacific: Country Analysis
    • 8.3.1. China Helicobacter Pylori Diagnostics Market Outlook
      • 8.3.1.1. Market Size & Forecast
        • 8.3.1.1.1. By Value
      • 8.3.1.2. Market Share & Forecast
        • 8.3.1.2.1. By Type
        • 8.3.1.2.2. By Technology
        • 8.3.1.2.3. By End user
    • 8.3.2. India Helicobacter Pylori Diagnostics Market Outlook
      • 8.3.2.1. Market Size & Forecast
        • 8.3.2.1.1. By Value
      • 8.3.2.2. Market Share & Forecast
        • 8.3.2.2.1. By Type
        • 8.3.2.2.2. By Technology
        • 8.3.2.2.3. By End user
    • 8.3.3. Japan Helicobacter Pylori Diagnostics Market Outlook
      • 8.3.3.1. Market Size & Forecast
        • 8.3.3.1.1. By Value
      • 8.3.3.2. Market Share & Forecast
        • 8.3.3.2.1. By Type
        • 8.3.3.2.2. By Technology
        • 8.3.3.2.3. By End user
    • 8.3.4. South Korea Helicobacter Pylori Diagnostics Market Outlook
      • 8.3.4.1. Market Size & Forecast
        • 8.3.4.1.1. By Value
      • 8.3.4.2. Market Share & Forecast
        • 8.3.4.2.1. By Type
        • 8.3.4.2.2. By Technology
        • 8.3.4.2.3. By End user
    • 8.3.5. Australia Helicobacter Pylori Diagnostics Market Outlook
      • 8.3.5.1. Market Size & Forecast
        • 8.3.5.1.1. By Value
      • 8.3.5.2. Market Share & Forecast
        • 8.3.5.2.1. By Type
        • 8.3.5.2.2. By Technology
        • 8.3.5.2.3. By End user

9. Middle East & Africa Helicobacter Pylori Diagnostics Market Outlook

  • 9.1. Market Size & Forecast
    • 9.1.1. By Value
  • 9.2. Market Share & Forecast
    • 9.2.1. By Type
    • 9.2.2. By Technology
    • 9.2.3. By End user
    • 9.2.4. By Country
  • 9.3. Middle East & Africa: Country Analysis
    • 9.3.1. Saudi Arabia Helicobacter Pylori Diagnostics Market Outlook
      • 9.3.1.1. Market Size & Forecast
        • 9.3.1.1.1. By Value
      • 9.3.1.2. Market Share & Forecast
        • 9.3.1.2.1. By Type
        • 9.3.1.2.2. By Technology
        • 9.3.1.2.3. By End user
    • 9.3.2. UAE Helicobacter Pylori Diagnostics Market Outlook
      • 9.3.2.1. Market Size & Forecast
        • 9.3.2.1.1. By Value
      • 9.3.2.2. Market Share & Forecast
        • 9.3.2.2.1. By Type
        • 9.3.2.2.2. By Technology
        • 9.3.2.2.3. By End user
    • 9.3.3. South Africa Helicobacter Pylori Diagnostics Market Outlook
      • 9.3.3.1. Market Size & Forecast
        • 9.3.3.1.1. By Value
      • 9.3.3.2. Market Share & Forecast
        • 9.3.3.2.1. By Type
        • 9.3.3.2.2. By Technology
        • 9.3.3.2.3. By End user

10. South America Helicobacter Pylori Diagnostics Market Outlook

  • 10.1. Market Size & Forecast
    • 10.1.1. By Value
  • 10.2. Market Share & Forecast
    • 10.2.1. By Type
    • 10.2.2. By Technology
    • 10.2.3. By End user
    • 10.2.4. By Country
  • 10.3. South America: Country Analysis
    • 10.3.1. Brazil Helicobacter Pylori Diagnostics Market Outlook
      • 10.3.1.1. Market Size & Forecast
        • 10.3.1.1.1. By Value
      • 10.3.1.2. Market Share & Forecast
        • 10.3.1.2.1. By Type
        • 10.3.1.2.2. By Technology
        • 10.3.1.2.3. By End user
    • 10.3.2. Colombia Helicobacter Pylori Diagnostics Market Outlook
      • 10.3.2.1. Market Size & Forecast
        • 10.3.2.1.1. By Value
      • 10.3.2.2. Market Share & Forecast
        • 10.3.2.2.1. By Type
        • 10.3.2.2.2. By Technology
        • 10.3.2.2.3. By End user
    • 10.3.3. Argentina Helicobacter Pylori Diagnostics Market Outlook
      • 10.3.3.1. Market Size & Forecast
        • 10.3.3.1.1. By Value
      • 10.3.3.2. Market Share & Forecast
        • 10.3.3.2.1. By Type
        • 10.3.3.2.2. By Technology
        • 10.3.3.2.3. By End user

11. Market Dynamics

  • 11.1. Drivers
  • 11.2. Challenges

12. Market Trends & Developments

  • 12.1. Merger & Acquisition (If Any)
  • 12.2. Product Launches (If Any)
  • 12.3. Recent Developments

13. Global Helicobacter Pylori Diagnostics Market: SWOT Analysis

14. Porter's Five Forces Analysis

  • 14.1. Competition in the Industry
  • 14.2. Potential of New Entrants
  • 14.3. Power of Suppliers
  • 14.4. Power of Customers
  • 14.5. Threat of Substitute Products

15. Competitive Landscape

  • 15.1. Thermo Fisher Scientific inc.
    • 15.1.1. Business Overview
    • 15.1.2. Products & Services
    • 15.1.3. Recent Developments
    • 15.1.4. Key Personnel
    • 15.1.5. SWOT Analysis
  • 15.2. Biohit Oyj
  • 15.3. Quest Diagnostics Incorporated
  • 15.4. Meridian Bioscience
  • 15.5. Bio-Rad Laboratories
  • 15.6. Alpha Laboratories Ltd
  • 15.7. F. Hoffmann-La Roche Ltd
  • 15.8. Coris BioConcept
  • 15.9. Certest Biotec
  • 15.10. Epitope Diagnostics, Inc

16. Strategic Recommendations

17. About Us & Disclaimer